Citadel Advisors’s eXoZymes Inc EXOZ Stock Holding History

Citadel Advisors’s Portfolio EXOZ Stock Details EXOZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,144	Closed	-$174K	–	14524
2025 Q2	$174K	Buy	+18,144	New	+$221K	﹤0.01%	10814
2025 Q1	–	Sell	-27,652	Closed	-$456K	–	15888
2024 Q4	$456K	Buy	+27,652	New	+$408K	﹤0.01%	8763

Other funds holding EXOZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's EXOZ Position: Q3 2025 in Review

Citadel Advisors sold out of eXoZymes Inc (EXOZ) in Q3 2025, closing a stake of 18,144 shares — an estimated $174K sold.

Citadel Advisors first reported a position in EXOZ in Q4 2024 and held it in 2 quarters. The position peaked at $456K in Q4 2024. 6 funds tracked by Wall St. Rank hold EXOZ as of Q3 2025.

Citadel Advisors reported no remaining eXoZymes Inc position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 18,144 eXoZymes Inc shares in Q3 2025, an estimated $174K.
Citadel Advisors first reported a position in eXoZymes Inc in Q4 2024 and held it in 2 quarters.
Citadel Advisors's eXoZymes Inc position peaked at $456K in Q4 2024.
6 funds tracked by Wall St. Rank held eXoZymes Inc as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.